Amiodarone – Supraventricular and ventricular arrhythmias

Drug Name (Brand)	Amiodarone *(Cordarone X®)*
Indication	Supraventricular and ventricular arrhythmias
Traffic Light Classification	Amber shared care
NICE TA (plus link)
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. NICE Clinical Guideline on Atrial Fibrillation published June 2006. Prescribers should familiarise themselves with prescribing and monitoring advice contained in the manufacturer’s Statement of Product Characteristics which is available via http://www.medicines.org.uk/emc/ Recommended Monitoring: Thyroid function, LFT, U&E – every 6 months Ophthalmological examination – annually ECG – periodically If pulmonary toxicity suspected, chest x-ray & lung function tests required. July 2014: The TAG noted NICE CG 180 (June 2014) – Management of Atrial Fibrillation May 2018: The TAG recommended that GP prescribing and monitoring guidance for amiodarone be developed to support local use in primary care under the new CCGs’ primary care drug monitoring LES. July 2018: The TAG supported a GP Prescribing and monitoring Guidance document to support its safe use in primary care. July 2018: The D&TC recommended that amiodarone should be classified as Level 3 under the CCGs’ Local Enhanced Service agreement with GP practices for monitoring drug treatments in primary care. Jan 2023 – Existing guidance merged with RMOC SCA to create new shared care agreement. Classification amended to amber
Date of TAG recommendation / ratification		1/1/2023	Review Date	1/4/2027